Enable JavaScript to ensure website accessibility
Precipio Integrates Cost Reducing And Fast Turnaround “High Resolution Melt” Into Liquid Biopsy Platform

Enhances competitive advantage as industry’s most cost effective solution NEW HAVEN, CT, (March 20th, 2018) – [...]

Precipio Settles Lawsuit With Crede Capital

Completes Restructuring of close to 95% Transgenomic Liabilities NEW HAVEN, CT, (March 13th, 2018) – Specialty [...]

Key Measure Of Precipio’s Pathology Sales Growth 4X Prior Quarter

Strong indications of academic-level pathology market adoption and sales uptake NEW HAVEN, CT, (February 22nd, [...]

Precipio Launches Unique Lung Cancer Monitoring Test For Therapy Resistance

New test fulfills promise of liquid biopsies to cost effectively monitor patients NEW HAVEN, CT, [...]

Precipio Announces Q4 2017 Revenue At 350% Of Previous Quarter

First post-merger quarter to turn the corner and demonstrate growth NEW HAVEN, CT, (February 09th, [...]

Precipio Enters Japanese Liquid Biopsy Market With First Hospital Sale

First ICE-COLD PCR™ order generated from distribution partnership with Sowa Trading Company NEW HAVEN, CT, [...]

Precipio Commences Validation Study Of Proprietary IV-Cell Cytogenetics Media At University Of Pennsylvania

NEW HAVEN, CT, (January 22nd, 2018) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it [...]

Precipio Appoints New Sales VP To Manage Diagnostics Sales Expansion

Sales growth acceleration plan to triple size of oncologist/hospital sales team in 2018 NEW HAVEN, [...]

Yale Study Demonstrates Four-Fold Superiority Of Academic Level Diagnostic Accuracy

Study further shows ~73% of cases which academic pathologists determined were previously misdiagnosed, have definite [...]